What ILS does

ILS Inc. (ILS株式会社) is a Tokyo-based, privately held Japanese life sciences company that operates three integrated business divisions: pharmaceuticals, functional food ingredients, and specialty chemicals. The company manufactures and sells active pharmaceutical ingredients (Parnaparin Sodium, Glucagon, Thrombin), formulated pharmaceuticals (Buserelin Nasal Solution, Glucagon Injection), and veterinary products (Itorelin Injection) under dual Japanese pharmaceutical manufacturing and marketing approval holder licenses. Its functional foods division supplies proprietary ingredients including heme iron (Hemron and Hemron 2HiWS), liver extract peptides (Liver Hi / レバーHi), three L-Carnitine variants, NMN in multiple grades, and curcumin — products backed by clinical absorption and efficacy studies. The chemicals division sources pharmaceutical and agrochemical intermediates from a network of 40+ Indian manufacturing partners coordinated through its wholly-owned subsidiary ILS INDIA PRIVATE LIMITED, established in Hyderabad in 2021.

ILS's business model centers on B2B sales to pharmaceutical companies, functional food manufacturers, and chemical buyers in Japan and select international markets. Revenue is generated through product sales, long-term exclusive distribution arrangements (notably the Sigma-Tau L-Carnitine partnership since 2003 and the Bachem peptide distribution agreement since 2015), and regulatory services including Accreditation of Foreign Manufacturers (AFM) proxy and In-Country Caretaker of Japanese Drug Master File (JDMF) for overseas suppliers. Customer acquisition is driven primarily by trade show participation (CPHI Japan, Food Development Expo, Vitafoods Asia, ifia JAPAN) and direct B2B inquiry. Finished product distribution is selective — for example, Heme Iron Jelly is manufactured by Maki Food Company in Niigata and sold through wholesale channels.

ILS operates GMP-compliant manufacturing and R&D at its Toride (formerly Moriya) site in Ibaraki Prefecture, with headquarters relocated to Tokyo in April 2019 to support business expansion. Ownership transferred in October 2018 when Otsuka Chemical Co., Ltd. sold all shares to Mountain Holdings Godo Kaisha (Goldman Sachs-related) and OPI2002 Investment Partnership (ORIX-related), making ILS a PE-backed platform. Kozo Yoshida has served as President and Representative Director since December 1, 2018. The combination of regulated manufacturing licenses, proprietary ingredient IP with clinical substantiation, and a Japan-India supply corridor forms the foundation of ILS's current strategic positioning.

Name

ILS

Legal name

ILS株式会社

Website

https://ils.co.jp

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1–10 employees

Short description

ILS Inc. is a PE-backed Japanese life sciences company that manufactures and sells pharmaceutical APIs and formulations, proprietary functional food ingredients (heme iron, liver extract, L-carnitine, NMN, curcumin), and India-sourced specialty chemicals to B2B customers in Japan and internationally.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Food Manufacturing (311)

SIC

Pharmaceutical Preparations (2834), Miscellaneous Food Preparations & Kindred Products (2090)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industries

Food-Grade Additives & Functional Ingredients Trading/Wholesale (AFAIAKAI), Food Ingredients, Additives & Industrial Food Wholesale Distribution (CRAOAAAL)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Functional food ingredients
• Nutritional supplements
• Chemical intermediates

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Pharmaceutical Products Manufacturing and Sales: Manufactures and sells pharmaceutical products including active pharmaceutical ingredients (APIs) such as Parnaparin Sodium, Glucagon, and Thrombin (Japanese Pharmacopoeia), as well as formulated pharmaceuticals (Buserelin Nasal Solution, Glucagon Injection) and veterinary pharmaceuticals (Itorelin Injection). Revenue is generated through product sales to distributors and healthcare institutions.
2. Functional Food Ingredients: Develops and sells functional food ingredients including Heme Iron (Hemron series), Liver Extract (レバーHi), L-Carnitine and its salts, NMN, Curcumin Powder 95, and finished products such as Heme Iron Jelly. Products are sold to food and supplement manufacturers.
3. Chemical Products Supply: Supplies pharmaceutical and agrochemical intermediates, chemical compounds, amino acids, and impurity reference standards sourced primarily from India, serving Japanese customers seeking high-quality chemical raw materials.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

ILS is a Japanese manufacturer that develops, produces, and sells active pharmaceutical ingredients (APIs), finished pharmaceutical formulations, functional food ingredients, supplements, and chemical intermediates across three business divisions. The company operates GMP/GQP/GVP-compliant manufacturing, supplies APIs such as Parnaparin Sodium, Glucagon, and Thrombin to pharmaceutical companies, distributes functional food ingredients including heme iron, L-carnitine variants, NMN, and curcumin to supplement manufacturers, and provides regulatory documentation services (AFM/JDMF preparation).

Product overview

ILS Inc. operates three core business divisions: Pharmaceuticals (製造販売), Functional Foods (功能性食品), and Chemicals (化学品). The pharmaceutical business encompasses active pharmaceutical ingredients (Parnaparin Sodium, Glucagon, Thrombin) and formulations (Buserelin Nasal Solution, Glucagon Injection, ITORELIN for animal use). The functional foods division offers a portfolio of health ingredients including Heme Iron materials (Hemron series), Liver Extract (Liver Hi), L-Carnitine in three variants, NMN in three types, Curcumin Powder 95, and finished products like Heme Iron Jelly. The chemicals division supplies pharmaceutical and agrochemical intermediates sourced primarily from India. The company emphasizes GMP-based quality assurance across all divisions, leveraging over 30 years of experience in life science business.

Differentiator

Problem solved

Functional benefit

Products and services

• Parnaparin Sodium
• Glucagon (API)
• Thrombin (API)
• Buserelin Nasal Solution
• Glucagon Injection
• Itorelin Injection
• AFM/JDMF Regulatory Documentation Services
• Heme Iron (Hemron)
• Heme Iron Jelly
• Liver Hi
• L-Carnitine (Fumarate and L-Tartrate variants)
• NMN (beta-Nicotinamide Mononucleotide)
• Curcumin Powder 95
• Chemical Intermediates

Quantifiable outcome

• Heme iron (Hemron) shows approximately 5x higher iron absorption rate compared to non-heme iron, as demonstrated in ILS's own 2008 crossover blind study measuring serum iron concentration changes in iron-deficient subjects.
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and major.

• 40+ Indian Manufacturers (Chemical Business)coreImplementation/ SI/ Consulting Partner · 1 January 2021ILS has established partnerships with over 40 reliable manufacturers in India for the chemicals business. Services provided include raw material procurement support, regulatory compliance assistance, technical review, quality control (QC), and audit support. These partnerships enable ILS to offer Japanese customers high-quality chemical intermediates and agrochemical compounds produced via high-risk reactions not feasible in Japan.
• Bachem Holding AG / Bachem Americas, Inc.majorStrategic or Co-development Partner · 28 February 2015ILS transferred 100% of American Peptide Company (APC) shares to Bachem Americas in February 2015. Concurrently, ILS expanded its partnership with Bachem to serve as Bachem's domestic Japan distribution agent for catalog peptide reagents, custom synthesis peptides, and large-scale GMP peptides. This partnership leverages Bachem's global leadership in peptides to supply Japanese pharmaceutical customers.
• Sigma-Tau (Italy)majorChannel Partner/ Reseller/ Distributor · 1 January 2003ILS entered an exclusive Japan distribution agreement with Sigma-Tau (Italy) for L-Carnitine and L-Carnitine Fumarate in 2003. Sigma-Tau is the manufacturer of these products. ILS has marketed these products in Japan since 2003 under this exclusive distribution arrangement. The partnership was later extended to include L-Carnitine L-Tartrate.

Scale indicators4 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• Otsuka Chemical Co., Ltd. Former parent of ILS (2008–2018) and recipient of the ILS peptide business via absorption-type split in 2018. Directly comparable as a Japanese specialty chemicals and peptide manufacturer sharing historical technology and customer overlap.
• Nichi-Iko Pharmaceutical Co., Ltd. One of Japan's largest generic pharmaceutical companies and ILS's exclusive sales partner for Buserelin Nasal Solution. Comparable as a Japanese-market pharma distributor with overlapping therapeutic categories (endocrinology, reproductive health).
• Bachem Holding AG: Swiss peptide and API manufacturer and ILS's exclusive Japan distribution partner (since 2015) for catalog peptides, custom synthesis, and GMP peptides. Directly comparable as a peptide-focused API/ingredient manufacturer with Japanese market exposure.
• Kaneka Corporation: Japanese specialty chemicals and life science company with pharmaceutical intermediates, amino acids, and functional food ingredient lines. Comparable as a Japan-based specialty ingredient supplier serving pharma and food manufacturers.
• Kaigen Pharma Co., Ltd. Japanese specialty pharmaceutical company and ILS's exclusive sales partner for Glucagon Injection. Comparable as a Japanese pharmaceutical distributor with overlapping therapeutic focus (endocrine, metabolic).
• NHU Co., Ltd. (Zhejiang NHU): Chinese specialty chemicals and nutrition ingredient manufacturer producing NMN, vitamins, and amino acid derivatives. Comparable as a large-scale Asian manufacturer competing with ILS in the NMN and curcumin ingredient market.
• Ajinomoto Co., Inc. Japanese amino acid and functional food ingredient manufacturer with global presence. Overlaps with ILS in amino acid-derived functional ingredients (L-Carnitine, peptides) and supply to Japanese functional food manufacturers.
• Alfasigma S.p.A. (formerly Sigma-Tau): Italian pharmaceutical company that has supplied ILS with L-Carnitine and L-Carnitine Fumarate under exclusive Japan distribution since 2003. Directly comparable as the source-side manufacturer of L-Carnitine, a key ILS functional food ingredient.

Broad incumbents

• Kyowa Kirin Co., Ltd. Japanese specialty pharmaceutical company with strong endocrinology, nephrology, and rare disease franchises. Comparable as a Japanese pharma player operating in adjacent therapeutic categories to ILS's Buserelin and Glucagon franchises, though at significantly larger scale.
• Lonza Group AG: Swiss global API and ingredient manufacturer with established Japanese operations. Comparable as a multi-modality API/ingredient manufacturer serving pharma and nutrition customers, though at significantly larger scale and broader portfolio than ILS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/initiativeforlifesciences

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ILS